Cargando…

Circulating microparticle levels are reduced in patients with ARDS

BACKGROUND: It is unclear how to identify which patients at risk for acute respiratory distress syndrome (ARDS) will develop this condition during critical illness. Elevated microparticle (MP) concentrations in the airspace during ARDS are associated with activation of coagulation and in vitro studi...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaver, Ciara M., Woods, Justin, Clune, Jennifer K., Grove, Brandon S., Wickersham, Nancy E., McNeil, J. Brennan, Shemancik, Gregory, Ware, Lorraine B., Bastarache, Julie A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445431/
https://www.ncbi.nlm.nih.gov/pubmed/28545548
http://dx.doi.org/10.1186/s13054-017-1700-7
_version_ 1783238888718860288
author Shaver, Ciara M.
Woods, Justin
Clune, Jennifer K.
Grove, Brandon S.
Wickersham, Nancy E.
McNeil, J. Brennan
Shemancik, Gregory
Ware, Lorraine B.
Bastarache, Julie A.
author_facet Shaver, Ciara M.
Woods, Justin
Clune, Jennifer K.
Grove, Brandon S.
Wickersham, Nancy E.
McNeil, J. Brennan
Shemancik, Gregory
Ware, Lorraine B.
Bastarache, Julie A.
author_sort Shaver, Ciara M.
collection PubMed
description BACKGROUND: It is unclear how to identify which patients at risk for acute respiratory distress syndrome (ARDS) will develop this condition during critical illness. Elevated microparticle (MP) concentrations in the airspace during ARDS are associated with activation of coagulation and in vitro studies have demonstrated that MPs contribute to acute lung injury, but the significance of MPs in the circulation during ARDS has not been well studied. The goal of the present study was to test the hypothesis that elevated levels of circulating MPs could prospectively identify critically ill patients who will develop ARDS and that elevated circulating MPs are associated with poor clinical outcomes. METHODS: A total of 280 patients with platelet-poor plasma samples from the prospective Validating Acute Lung Injury biomarkers for Diagnosis (VALID) cohort study were selected for this analysis. Demographics and clinical data were obtained by chart review. MP concentrations in plasma were measured at study enrollment on intensive care unit (ICU) day 2 and on ICU day 4 by MP capture assay. Activation of coagulation was measured by plasma recalcification (clot) times. RESULTS: ARDS developed in 90 of 280 patients (32%) in the study. Elevated plasma MP concentrations were associated with reduced risk of developing ARDS (odds ratio (OR) 0.70 per 10 μM increase in MP concentration, 95% CI 0.50–0.98, p = 0.042), but had no significant effect on hospital mortality. MP concentration was greatest in patients with sepsis, pneumonia, or aspiration as compared with those with trauma or receiving multiple blood transfusions. MP levels did not significantly change over time. The inverse association of MP levels with ARDS development was most striking in patients with sepsis. After controlling for age, presence of sepsis, and severity of illness, higher MP concentrations were independently associated with a reduced risk of developing ARDS (OR 0.69, 95% CI 0.49–0.98, p = 0.038). MP concentration was associated with reduced plasma recalcification time. CONCLUSIONS: Elevated levels of circulating MPs are independently associated with a reduced risk of ARDS in critically ill patients. Whether this is due to MP effects on systemic coagulation warrants further investigation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13054-017-1700-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5445431
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54454312017-05-30 Circulating microparticle levels are reduced in patients with ARDS Shaver, Ciara M. Woods, Justin Clune, Jennifer K. Grove, Brandon S. Wickersham, Nancy E. McNeil, J. Brennan Shemancik, Gregory Ware, Lorraine B. Bastarache, Julie A. Crit Care Research BACKGROUND: It is unclear how to identify which patients at risk for acute respiratory distress syndrome (ARDS) will develop this condition during critical illness. Elevated microparticle (MP) concentrations in the airspace during ARDS are associated with activation of coagulation and in vitro studies have demonstrated that MPs contribute to acute lung injury, but the significance of MPs in the circulation during ARDS has not been well studied. The goal of the present study was to test the hypothesis that elevated levels of circulating MPs could prospectively identify critically ill patients who will develop ARDS and that elevated circulating MPs are associated with poor clinical outcomes. METHODS: A total of 280 patients with platelet-poor plasma samples from the prospective Validating Acute Lung Injury biomarkers for Diagnosis (VALID) cohort study were selected for this analysis. Demographics and clinical data were obtained by chart review. MP concentrations in plasma were measured at study enrollment on intensive care unit (ICU) day 2 and on ICU day 4 by MP capture assay. Activation of coagulation was measured by plasma recalcification (clot) times. RESULTS: ARDS developed in 90 of 280 patients (32%) in the study. Elevated plasma MP concentrations were associated with reduced risk of developing ARDS (odds ratio (OR) 0.70 per 10 μM increase in MP concentration, 95% CI 0.50–0.98, p = 0.042), but had no significant effect on hospital mortality. MP concentration was greatest in patients with sepsis, pneumonia, or aspiration as compared with those with trauma or receiving multiple blood transfusions. MP levels did not significantly change over time. The inverse association of MP levels with ARDS development was most striking in patients with sepsis. After controlling for age, presence of sepsis, and severity of illness, higher MP concentrations were independently associated with a reduced risk of developing ARDS (OR 0.69, 95% CI 0.49–0.98, p = 0.038). MP concentration was associated with reduced plasma recalcification time. CONCLUSIONS: Elevated levels of circulating MPs are independently associated with a reduced risk of ARDS in critically ill patients. Whether this is due to MP effects on systemic coagulation warrants further investigation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13054-017-1700-7) contains supplementary material, which is available to authorized users. BioMed Central 2017-05-25 /pmc/articles/PMC5445431/ /pubmed/28545548 http://dx.doi.org/10.1186/s13054-017-1700-7 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Shaver, Ciara M.
Woods, Justin
Clune, Jennifer K.
Grove, Brandon S.
Wickersham, Nancy E.
McNeil, J. Brennan
Shemancik, Gregory
Ware, Lorraine B.
Bastarache, Julie A.
Circulating microparticle levels are reduced in patients with ARDS
title Circulating microparticle levels are reduced in patients with ARDS
title_full Circulating microparticle levels are reduced in patients with ARDS
title_fullStr Circulating microparticle levels are reduced in patients with ARDS
title_full_unstemmed Circulating microparticle levels are reduced in patients with ARDS
title_short Circulating microparticle levels are reduced in patients with ARDS
title_sort circulating microparticle levels are reduced in patients with ards
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445431/
https://www.ncbi.nlm.nih.gov/pubmed/28545548
http://dx.doi.org/10.1186/s13054-017-1700-7
work_keys_str_mv AT shaverciaram circulatingmicroparticlelevelsarereducedinpatientswithards
AT woodsjustin circulatingmicroparticlelevelsarereducedinpatientswithards
AT clunejenniferk circulatingmicroparticlelevelsarereducedinpatientswithards
AT grovebrandons circulatingmicroparticlelevelsarereducedinpatientswithards
AT wickershamnancye circulatingmicroparticlelevelsarereducedinpatientswithards
AT mcneiljbrennan circulatingmicroparticlelevelsarereducedinpatientswithards
AT shemancikgregory circulatingmicroparticlelevelsarereducedinpatientswithards
AT warelorraineb circulatingmicroparticlelevelsarereducedinpatientswithards
AT bastarachejuliea circulatingmicroparticlelevelsarereducedinpatientswithards